Clinical trial · Observational
Efficacy and Safety of Argon Plasma Coagulation in the Treatment of Patients With Hemoptysis Caused by Endobronchial Malignancies
Prospective, Observational Study on the Efficacy, the Safety and the Predictors of Success of Argon Plasma Coagulation in the Treatment of Patients With Hemoptysis Caused by Endobronchial Malignancies
NCT03625947CI-TRIAL-00068370terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Recruitment issues during pandemic (2020-2021)
Summary
Brief summary (as posted)
The aim of this study is to evaluate the efficacy, the safety and the main predictors of success of bronchoscopic Argon Plasma Coagulation in patients with hemoptysis caused by endobronchial malignancies.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Hemoptysis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Argon Plasma Coagulation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Hemoptysis patients
- description
- Hemoptysis patients caused by endobronchial malignancies
- interventionNames
- Other: Argon Plasma Coagulation
Primary outcomes (1)
- measure
- Percentage of patients with bleeding cessation without recurrence at 48 after bronchoscopic Argon Plasma Coagulation
- timeFrame
- 48 hours
- description
- Percentage of patients with bleeding cessation without recurrence at 48 hours after bronchoscopic Argon Plasma Coagulation employed to stop hemoptysis caused by endobronchial malignancies
Secondary outcomes (4)
- measure
- Incidence of adverse events
- timeFrame
- 48 hours
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients with hemoptysis caused by endobronchial (i.e. identifiable with flexible bronchoscopy) malignancies, without coagulopathy or other medically correctable causes of bleeding, who need endoscopic intervention with Argon Plasma Coagulation to stop bleeding * Adult patients who are able to tolerate bronchoscopy * Adult patients who are able to sign the written informed consent for the study participation Exclusion Criteria: * Patients with hemoptysis caused by endobronchial malignancies with coagulopathy or other medically correctable causes of bleeding. * Patients who are not able to tolerate bronchoscopy * Patients with hemoptysis without identifiable endobronchial malignancies during flexible bronchoscopy * Patients with Pace-Maker and/or Automated Implantable Cardioverter- Defibrillator(AICD) * Patients who refuse/are not able to sign the informed consent for the study participation
References
Publications (0)
Data not yet available
No reference posted for this study.